Gilead Says FDA Expands Approval of Chronic Hep-B Infection Treatment for Use in Kids

By Will Feuer

Gilead Sciences said the Food and Drug Administration has approved the expanded use of Vemlidy, its treatment for chronic hepatitis B virus infection, in certain kids ages six and older.

Kids treated with the once-daily 25 mg tablet need to weigh at least 25 kg and have compensated liver disease, Gilead said.

Vemlidy was approved by the FDA in 2016 as a once-daily treatment for adults with chronic HBV infection with compensated liver disease. In 2022, the FDA expanded the approval to kids 12 and older.

Write to Will Feuer at [e-mail]

(END) Dow Jones Newswires

03-28-24 0906ET